evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1 questions · 1 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Mesalamine (4 ‐ 4.5 g/day) vs budesonide

Induction of clinical remission (CDAI < or = 150) · patients with Induction of remission or response in Crohn's disease

Mesalamine (4 ‐ 4.5 g/day) showed no clear difference in induction of remission (CDAI < or = 150) ‐ Salofalk (4.5 g/day) compared with budesonide (moderate certainty).

1 finding from 1 review